Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07300267 · ClinicalTrials.gov registry record · Phase 1
A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)
A Phase 1 study of Pneumococcal Infection, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 210
- Enrollment target
- 12
- Study locations
NCT07300267 is a Phase 1 study of Pneumococcal Infection that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 210 participants. The trial reports 12 study locations across 9 states.
The verdict
NCT07300267, a Phase 1 study of Pneumococcal Infection, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 210 participants
- Enrollment target
- 12
- Study locations
Study Summary
Researchers are looking for new vaccines to prevent pneumococcal disease, which is any infection in the lungs or other parts of the body that is caused by a type of bacteria called Streptococcus pneumoniae. V118C is a new vaccine designed to help prevent disease from Streptococcus pneumoniae bacteria. This study will look at V118C in toddlers and infants. The goal of the study is to learn how safe V118C is for children and how well they tolerate it.
Conditions Studied
Interventions
- BIOLOGICAL V118C (Stage 1)
- BIOLOGICAL V118C (Stage 2)
- BIOLOGICAL PCV20 (Stage 1)
- BIOLOGICAL PCV20 (Stage 2)
Study Locations (12)
Texas
- Epic Medical Research - Carrollton ( Site 1038) - Carrollton
- Epic Medical Research- Garland ( Site 1017) - Garland
- University of Texas Medical Branch ( Site 1020) - League City
South Carolina
- Tribe Clinical Research, LLC-Pediatrics ( Site 1008) - Greenville
- Tribe Clinical Research - Spartanburg ( Site 1001) - Spartanburg
California
- Madera Family Medical Group ( Site 1004) - Madera
Florida
- Acevedo Clinical Research Associates ( Site 1029) - Miami
Kansas
- Cotton O'Neil Research Center ( Site 1039) - Topeka
Kentucky
- University of Louisville, Norton Children's Research Institute ( Site 1005) - Louisville
Missouri
- Saint Louis University Center for Vaccine Development ( Site 1031) - St Louis
New York
- Child Health Care Associates ( Site 1035) - East Syracuse
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Start Date | 2026-01-13 |
| Est. Completion | 2029-05-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07300267
The ClinicalTrials.gov registry entry for NCT07300267 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 210 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pneumococcal Infection appearing as the primary indexed condition, and to 4 interventions - of which V118C (Stage 1) is the first listed.
NCT07300267 reports 12 study locations spanning 9 distinct geographic areas - top geographies include Texas, South Carolina, California.
Frequently Asked Questions
What is clinical trial NCT07300267 about?
NCT07300267 is a clinical study titled "A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)". Researchers are looking for new vaccines to prevent pneumococcal disease, which is any infection in the lungs or other parts of the body that is caused by a type of bacteria called Streptococcus pneumoniae. V118C is a new vaccine designed to help prevent disease from Streptococcus pneumoniae bacteri...
What is the current status of trial NCT07300267?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 210 participants. The study started on 2026-01-13. Estimated completion is 2029-05-25.
What conditions does trial NCT07300267 study?
This clinical trial studies the following conditions: Pneumococcal Infection.
What interventions are being tested in trial NCT07300267?
The interventions under investigation include: V118C (Stage 1) (BIOLOGICAL), V118C (Stage 2) (BIOLOGICAL), PCV20 (Stage 1) (BIOLOGICAL), PCV20 (Stage 2) (BIOLOGICAL).
Who is sponsoring clinical trial NCT07300267?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07300267 being conducted?
This trial has 12 study locations across California, Florida, Kansas, Kentucky, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pneumococcal Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.